GLP-1 medicines are widely used for type 2 diabetes and obesity. A new Australian safety update asks clinicians and patients to pay attention to a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION.
The important message is balanced: the condition is rare, the available evidence does not prove that every GLP-1 medicine causes it, and people should not stop a medicine on their own. But sudden or partial vision loss needs urgent medical assessment.
What is NAION?
NAION happens when blood flow to part of the optic nerve is interrupted. The optic nerve carries visual information from the eye to the brain. The resulting vision loss can be permanent, and treatment has not been shown to restore visual acuity reliably.
What did the safety update say?
On 23 July 2026, Australia’s Therapeutic Goods Administration (TGA) reported that product warnings across the GLP-1 receptor agonist class had been updated because of the potential for a rare but serious eye disorder. The medicines covered in the update include dulaglutide, semaglutide, tirzepatide and liraglutide products marketed in Australia.
The TGA reported 36 cases of optic ischemic neuropathy in its adverse-event database: 23 involving semaglutide, three involving liraglutide and 10 involving tirzepatide. No cases were found for dulaglutide in that search, although one semaglutide report involved previous dulaglutide use.
These reports are important for safety monitoring, but they cannot by themselves show how often the condition occurs or prove that a medicine caused it. The TGA said the evidence was conflicting and that some epidemiological studies supported a possible signal for semaglutide, but not for dulaglutide or tirzepatide.
Who may be at higher risk?
The TGA notes that people with an anatomical feature sometimes called a “disc at risk” are more vulnerable to NAION whether or not they take a GLP-1 medicine. An optometrist or ophthalmologist can assess this feature. Diabetes and other vascular risk factors may also matter.
What symptoms need urgent attention?
- Sudden loss of vision in one eye
- A sudden partial loss or missing area in the field of vision
- New visual symptoms that develop quickly, especially on waking
If this happens, seek urgent medical attention and tell the clinician which medicines you take. The Australian semaglutide product information says treatment should be discontinued if NAION is confirmed. That is a clinician-led decision after assessment, not a reason to stop treatment without advice when no warning symptoms are present.
What should people taking a GLP-1 medicine do now?
- Continue the medicine as prescribed unless your own clinician tells you otherwise.
- Know the urgent warning sign: sudden or partial vision loss.
- Keep routine eye and diabetes reviews, particularly if you already have eye disease or vascular risk factors.
- Ask your diabetes or eye-care team whether you have any individual risk factors for NAION.
Bottom line
NAION is a rare but potentially serious eye disorder that has been reported in people using GLP-1 medicines. The safety update does not show that these medicines commonly cause blindness, and it does not mean that people should stop effective treatment without medical advice. Sudden or partial vision loss is an emergency symptom and should be assessed promptly.
Sources:
- Therapeutic Goods Administration: GLP-1 RAs and rare vision disorder
- JAMA Ophthalmology: Risk of NAION in patients prescribed semaglutide
- American Diabetes Association: Standards of Care in Diabetes – 2026, Pharmacologic Approaches to Glycemic Treatment
This article is for general information and does not replace advice from a qualified healthcare professional.